Author + information
- Received February 9, 2018
- Revision received April 12, 2018
- Accepted April 12, 2018
- Published online July 2, 2018.
- Christian Shetelig, MDa,b,c,d,∗ (, )@UniOslo,
- Shanmuganathan Limalanathan, MD, PhDa,e,
- Pavel Hoffmann, MD, PhDa,f,
- Ingebjørg Seljeflot, PhDa,b,c,d,
- Jon M. Gran, MSc, PhDg,
- Jan Eritsland, MD, PhDa,c and
- Geir Ø. Andersen, MD, PhDa,c
- aDepartment of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway
- bCenter for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway
- cCenter for Heart Failure Research, Oslo, Norway
- dFaculty of Medicine, University of Oslo, Oslo, Norway
- eNational Association for Heart and Lung Diseases Clinics, Feiring Heart Clinic, Feiring, Norway
- fDepartment of Cardiology, Section of Interventional Cardiology, Oslo University Hospital Ullevål, Oslo, Norway
- gOslo Center for Biostatistics and Epidemiology, Oslo University Hospital and University of Oslo, Oslo, Norway
- ↵∗Address for correspondence:
Dr. Christian Shetelig, Department of Cardiology, Oslo University Hospital Ullevål, P.O. Box 4956, Nydalen, 0424 Oslo, Norway.
Background Little is known about the role of interleukin (IL)-8 in patients with acute ST-segment elevation myocardial infarction (STEMI).
Objectives The aims of this study were to evaluate, in STEMI patients, the temporal profile of IL-8 and possible associations with left ventricular (LV) function and remodeling, infarct size, microvascular obstruction, myocardial salvage, and future clinical events.
Methods A total of 258 patients with STEMI were included. Blood samples were drawn before and immediately after percutaneous coronary intervention (PCI), at day 1, and after 4 months. Cardiac magnetic resonance imaging was performed in the acute phase and after 4 months. Clinical events were registered during 12 months’ follow-up and all-cause mortality after median 70 months’ follow-up.
Results Patients with IL-8 levels greater than the median measured both immediately after PCI and at day 1 had larger final infarct size, lower LV ejection fraction, larger increase in LV end-diastolic volume, and higher frequency of microvascular obstruction. After multivariate adjustment, high IL-8 levels at day 1 were associated with an increased risk of developing a large MI and having reduced LV ejection fraction at 4 months, also after adjustment for peak troponin value. Patients with IL-8 levels in the highest quartile measured at all sampling points were more likely to have a clinical event during the first 12 months after the MI and had lower overall survival during long-term follow-up.
Conclusions High levels of circulating IL-8 were associated with large infarct size, impaired recovery of LV function, and adverse clinical outcome in patients with STEMI, suggesting IL-8 as a future therapeutic target based on its important role in post-infarction inflammation.
This work was supported by Stein Erik Hagen Foundation for Clinical Heart Research, Oslo, Norway, The Norwegian Health and Rehabilitation Foundation and Center for Heart Failure Research, University of Oslo, Norway. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received February 9, 2018.
- Revision received April 12, 2018.
- Accepted April 12, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.